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Abstract
Oligoprogressive disease is a relatively new clinical concept describing progression at only a few sites of metastasis in patients with otherwise controlled
widespread disease. In the era of well-tolerated targeted treatments, resistance inevitably occurs and overcoming this is a challenge. Local ablative therapy for
oligoprogressive disease may allow the continuation of systemic treatments by overcoming the few sub-clones that have developed resistance. Stereotactic body
radiotherapy is now frequently used in treating oligometastatic disease using ablative doses with minimally invasive techniques and acceptable toxicity. We
discuss the current retrospective clinical evidence base supporting the use of local ablative therapy for oligoprogression in metastatic patients on targeted
treatments within multiple tumour sites. As there is currently a lack of published prospective data available, the best management for these patients remains
unclear. We discuss current trials in recruitment and the potential advancements in treating this group of patients with stereotactic radiotherapy.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Clinical Oncology, https://doi.org/10.1016/j.clon.2019.05.015Oligoprogressive Disease versus
Oligometastatic Disease: what is the
Difference?
The description of oligometastatic disease (OMD) has
evolved from its inception. It was initially described as an
intermediate disease state between localised and wide-
spread disease [1]. It is considered as metastatic disease
conﬁned to a limited number of sites (often described as up
to three or ﬁve sites) and can be synchronous or meta-
chronous with the primary tumour presentation. Recog-
nising OMD is of clinical importance, as patients can be
considered for local ablative treatments such as stereotactic
body radiotherapy (SBRT) or surgery, ideally within a clin-
ical trial. The evidence base suggests a better prognosis with
potentially curative outcomes using ablative strategies
across a variety of tumour sites. There are many systematic
and retrospective reviews presenting survival outcomes for
patients treated by surgical resection, SBRT ord. This is an open access article under the CC BY-NC-ND license (http://
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long-term survival beneﬁts [2e10].
In addition, there are two phase II randomised prospec-
tive studies of synchronous oligometastatic non-small cell
lung cancer (NSCLC). Gomez et al. [11] randomised patients
with synchronous oligometastatic NSCLC after a response to
ﬁrst-line systemic treatment to local consolidative treat-
ment with radiotherapy or surgical resection of all lesions
or a combination of both  maintenance treatment versus
standard of care (maintenance treatment or observation
alone). The trial was terminated early due to signiﬁcant
median progression-free survival (PFS) differences between
arms; the median PFS for local consolidative treatment was
11.9 months (90% conﬁdence interval 5.7e20.9) versus 3.9
months in the standard of care arm (90% conﬁdence interval
2.3e6.6). Adverse events were similar between the groups.
A similar phase II study [12] randomised patients with up to
ﬁve sites of OMD to maintenance chemotherapy and SBRT
or maintenance chemotherapy alone. This study also
stopped early due to ﬁnding a signiﬁcant improvement in
PFS (9.7 versus 3.5 months, P ¼ 0.01) within the SBRT arm,
with similar toxicity in both groups. Current trials in prog-
ress include CORE (NCT02759783) and SABR-COMET
(NCT01446744), addressing the clinical question of SBRT
use on PFS and overall survival in OMD for multiple tumour
sites. SABR-COMET [13] has completed recruitment. Pa-
tients with between one and ﬁve metastatic lesions were
treated with palliative standard of care, which included
palliative radiotherapy or palliative chemotherapy as indi-
cated, or arm 2, SBRT to all metastatic lesions  palliative
chemotherapy [58]. Of 99 patients randomised, the median
overall survival in the standard arm was 28 months (95%
conﬁdence interval 19e33 months) versus 41 months (95%
conﬁdence interval 26enot reached months) in the SBRT
arm. There were three treatment-related National Cancer
Institute CommonToxicity Criteria (NCI-CTC) grade 5 events
in the SBRT arm. These included death due to radiation
pneumonitis, pulmonary abscess and subdural haemor-
rhage after surgery to repair a SBRT-related perforated
gastric ulcer.
By contrast, oligoprogressive disease (OPD) is a relatively
new clinical concept and is distinct from OMD as deﬁned by
Hellman and Weichselbaum [1]. OPD develops on a back-
ground of polymetastatic disease. OPD occurs following an
initial response to systemic treatment where disease pro-
gression only occurs in a limited number of sites. OPD is
increasingly encountered in clinical practice due to the
widespread use of ﬁrst- and second-generation molecular
targeted treatments [14,15] with the potential for the
development of sub-clones of drug resistance. OPD patients
are considered to have a more advanced disease status
compared with patients with OMD, by virtue of the fact that
they initially present with polymetastatic disease [16e19].
Identifying patients with OPDmay be important because
there is potential to prevent the development of wide-
spread resistant disease from the propagation of drug-
resistant clones. Removing or ablating OPD sites may slow
or prevent this process, allowing prolonged therapeutic
beneﬁt from the current line of systemic therapy. ThisPlease cite this article as: Patel PH et al., The Dandelion Dilemma Revisit
Clinical Oncology, https://doi.org/10.1016/j.clon.2019.05.015beneﬁt may persist until a further stochastic clonal event
occurs or already disseminated resistant clones become
clinically or radiologically apparent, or until treatment be-
comes intolerable [20].
There remain clinical controversies in the optimal man-
agement of OPD due to a lack of prospective data. It is
important to recognise and distinguish between the
different disease patterns as management strategies differ.
This review will examine the evidence base regarding the
treatment of OPD, with a particular focus on lung and
prostate cancer, and will highlight the current issues with
OPD management, speciﬁcally whether to treat disease
with a change of systemic therapies (‘spray the whole
lawn’) or offer local ablative treatment (‘selective weeding’)
[21]. Figure 1 highlights the different disease patterns and
time points when local ablative therapy could be considered
in a patient’s pathway and can be used as a framework and
vocabulary for discussing OPD.Systemic Drug Resistance and
Oligoprogressive Disease
There is an expanding armamentarium of molecularly
targeted systemic treatments available to patients with
metastatic cancers across a number of different tumour
types. Anti-androgen targeted therapies have proven overall
survival and PFS beneﬁt in prostate cancer patients [22e25].
Anti-HER2 targeted treatments, such as pertuzumab in
combinationwith trastuzumab and docetaxel chemotherapy,
for metastatic HER-2-positive breast cancer have shown an
improvement in median overall survival of 15.7 months
compared with placebo [26]. Tyrosine kinase inhibitor (TKI)
treatment in epidermal growth factor receptor (EGFR) and
anaplastic lymphoma kinase (ALK) mutation-positive meta-
static NSCLC patients has resulted in a PFS of 8e13 months,
an improvement compared with standard chemotherapy
with higher response rates [27e30].
Although patients may show an initial response to tar-
geted therapies, secondary failure due to drug resistance
remains a problem. Acquired resistance to TKI in NSCLC
patients develops after a median of 8e13 months [27,29].
Three main genomic resistance mechanisms have been
identiﬁed, including target receptor alteration, activation of
bypass signalling pathways and phenotypic transformation
[31,32]. Other causes include increased drug efﬂux and
change in drug absorption [33]. In a similar manner to
tumour genomic heterogeneity [34], intra-patient drug
resistance can be variable and therefore isolated sites of
distinct drug-resistant clones can develop [31,35]. Similar
mechanisms of resistance involving androgen receptors and
the activation of androgen deprivation therapy resistance
pathways have been described in patients with castrate-
resistant prostate cancer (CRPC) treated with abiraterone
or enzalutamide [36]. Multiple mechanisms of resistance,
including poor internalisation of trastuzumab and HER-2
receptor complex at the cell surface and intracellular
transportation of trastuzumab in metastatic breast cancer
patients, have also been explored [37].ed for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Fig 1. Schematic of nomenclature in the metastatic state.
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tant clones regardless of the mutational genotype or load.
Therefore this may be an attractive additional treatment
option for patients before considering systemic treatment
change [38]. In practice, the conventional approach to pa-
tients presenting with OPD varies depending on a number
of patient factors, the tumour type and the number of
subsequent lines of systemic treatments available. In many
cases, at the onset of OPD the current line of systemic
treatment is discontinued and a switch to a further line of
systemic therapy is considered. The alternative strategy is to
continue the systemic treatment beyond progression.
NSCLC patients with EGFR mutations who continue TKI
beyond ﬁrst progression have been suggested to have a
survival beneﬁt compared with patients who stop TKI in
retrospective studies [39,40]. Tumour ﬂare, which can occur
with the interruption of TKI, may play a role in this [41]. A
prospective phase II study enrolled 208 patients in this
setting. There were 171 progressive disease events by
Response Evaluation Criteria In Solid Tumours (RECIST) v1.1
while on erlotinib. Of these patients, clinicians chose to
continue erlotinib in 93 (54%) patients beyond progression.
Post-hoc analysis found that the median time from starting
erlotinib to ﬁrst progression by RECIST v1.1 in these 93
patients was 11 months, with an addition of a median of 3.1
months if continuing erlotinib until further progression
[42]. The Prostate Cancer Clinical Trials Working Group 3
(PCWG3) advised to consider continuation of systemic tar-
geted treatments for patients with prostate cancer who are
continuing to beneﬁt symptomatically, even in the presence
of prostate-speciﬁc antigen or imaging progression [43].
PCWG3 also discussed the option of surgery or radiotherapy
to ablate oligoprogressing metastases.Diagnosis and Frequency of
Oligoprogressive Disease
Identifying OPD poses a challenge as the conventional
approach of using RECIST (a commonly used international
standard to determine a patient’s outcome from treatment)
has not been adapted to report on OPD [44]. For example, a
patient with progression of over 50% in a solitary lesion
with all other metastatic lesions showing continued
response by a reduction of more than 75% could be reported
as a partial response or stable disease after summing all the
longest diameters of the individual lesions. In practice,
however, knowing if there is progression of a solitary lesion
in the context of response or stable disease elsewhere,
compared with widespread progression, would highlight
different treatment options. Similarly, many patients who
have progressed by RECIST v1.1 may continue treatment
with targeted therapies beyond progression, indicating the
need for further radiological criteria to identify OPD and aid
treatment decisions [45]. A recent review [46] discussed the
limitations of RECIST v1.1 in the era of targeted treatments
with regards to both extra-cranial OPD (EC-OPD) and intra-
cranial metastases.Please cite this article as: Patel PH et al., The Dandelion Dilemma Revisit
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modality best distinguishes OPD from widespread pro-
gression and hence which patients may beneﬁt from local
therapy. The most commonly used imaging modalities in
routine clinical practice for patients with widespread dis-
ease for most tumour sites include computed tomography
and bone scans. This poses a considerable challenge in
certain tumour sites such as prostate cancer, where bone
progression is difﬁcult to assess and is unmeasurable by
RECIST v1.1 [47].
Assessing how often the OPD pattern arises clinically is
challenging due to its relatively recent description as a
clinical disease state and its variable deﬁnitions in the
literature. In addition, due to the lack of clear imaging
criteria for the disease pattern, the large systemic therapy
studies of molecular targeted agents have not reported the
proportion of patients who develop OPD or the suitability of
any oligoprogressive lesions for ablative approaches.
A retrospective review of computed tomography scans
for EGFR mutation-positive NSCLC patients enrolled in
prospective TKI trials documented patterns of progression
[14]. The study included 49 patients with serial computed
tomography scans and measurable disease; 11/49 (22.5%)
patients had progression isolated initially to the primary
site alone and not in distant metastases. A further retro-
spective review included 104 patients who had progressed
on TKI by RECIST v1.1, 16 (15%) of these patients had an
asymptomatic solitary site of EC-OPD [48]. A similar retro-
spective review investigated the pattern of progression in
108 oestrogen/progesterone-positive patients with meta-
static breast cancer who had progressed on endocrine
therapy [15]. OPD was deﬁned as three or fewer sites of
progression on a background of having more than six sites
of disease before therapy. The study reported that 23/108
(21%) patients developed OPD; 14 of these patients were
deemed suitable for local therapy. The most common site of
OPDwas in bone (nine), liver (ﬁve), locoregional (three) and
lung (two) metastases. OPD patterns in 35 men with
chemotherapy naïvemetastatic CRPC on abiraterone and 20
men on abiraterone post-docetaxel chemotherapy were
reported in a retrospective analysis [49]. Progression was
assessed using RECIST v1.1 and/or PCWG2 criteria, and OPD
was considered if ﬁve or fewer sites of disease were pro-
gressing. PCWG2 criteria emphasise the need for studies to
use end points such as failure to progress or delay of disease
progression for non-cytotoxic drugs, as demonstrating the
shrinkage of lesions, especially bone lesions, is not feasible
or necessary. In total, 12/35 (34%) chemotherapy naïve
metastatic CRPC patients met the criteria for OPD. By
contrast, within the cohort of 20 patients who had previ-
ously received chemotherapy, only one patient presented
with OPD. It is probable that OPD will become less common
after subsequent lines of therapy, due to the increased
heterogeneity of the tumour with time and exposure to
different drug treatments.
Prospective studies documenting the frequency and
characteristics of OPD in different tumour types are needed
to identify patients who may beneﬁt from local ablativeed for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Table 1
Retrospective studies of local ablative therapy for oligoprogression
Reference Patient tumour
type
No. OPD sites
included
No. patients
with PD
No. patients
with EC-OPD
Targeted therapy Local treatment
received
Median PFS 2
(months)
Systemic
treatment-
free survival
(months)
No. patients
(%) with grade
3/4 toxicity
[20]
Single centre
2005e2011
ALK þ, EGFR
þ NSCLC
4 EC or any
number of CNS
n ¼ 25 n ¼ 15
(3 patients
CNS þ EC-OPD)
Crizotinib or
erlotinib
SBRT: 12
XRT: 2
Surgery: 1
4 (CI 2.7e7.4)
(3 patients
CNS þ EC-OPD)
Grade 3 fatigue:
2 (8)
[32]
Single centre
EGFR þ
NSCLC
4 EC n ¼ 184 n ¼ 18 Erlotinib or
geﬁtinib
RFA: 2
SBRT: 1
XRT: 2
Surgery: 13
10 (95% CI 2e27) 22 (95%
CI 6e30)
Grade 3 pneumonia:
1 (5.5)
Grade 4 pneumonia:
1 (5.5)
[52]
Cohort analysis
two centres
2013e2015
EGFR þ
NSCLC
SBRT cohort: 
3 EC or CNS
No SBRT cohort:
any number of
sites
n ¼ 25 TKI
þ SBRT versus
n ¼ 25 SACT
switched
n ¼ 25
(includes
CNS disease)
TKI not speciﬁed SRS: 4
SBRT: 15
XRT: 6
7 versus 4.1
(CI NR) (TKI
þ SBRT versus
chemotherapy
for EC-OPD
and CNS)
Grade 3 oesophagitis:
1 (4)
[51]
Single centre
2009e2014
EGFR þ
NSCLC
5 EC or CNS n ¼ 46 n ¼ 22 TKI not speciﬁed SBRT: 8
XRT: 12
RFA: 2
7 (CI NR)
(CNS and
EC-OPD)
Grade 3 pneumonitis:
2 (4.3)
Grade 3 neutropenia:
10 (21.7)
Grade 4 skin rash:
2 (4.3)
[54]
Multicentre
2009e2015
NSCLC 4 EC
(oligometastases
or OPD or local
control
of dominant
tumour)
n ¼ 108 n ¼ 20 Erlotinib,
afatinib,
geﬁtinib,
pemetrexed
No SACT
SBRT: 20 3.3 (CI NR) Grade 3 late
respiratory
events: 2 (10)
Bone fracture:
3 (15)
[53]
Multicentre
2010e2016
CRPC 3 EC (bone or
LN only)
n ¼ 141 n ¼ 41 ADT SBRT: 41 11 (CI NR) 22 (CI NR) No grade 3/4
toxicity
[55]
Multicentre
2007e2015
RCC 3 EC or CNS n ¼ 55 n ¼ 51 Sunitinib,
pazopanib,
sorafenib
XRT: 25
Surgery: 25
Cryo/thermo-
ablation: 5
14 (95%
CI 6.9e21)
(EC-OPD
and CNS)
No toxicity data
reported
ADT, androgen deprivation therapy; ALK, anaplastic lymphoma kinase; CI, conﬁdence interval; CNS, central nervous system; CRPC, castrate-resistant prostate cancer; EC, extra-
cranial; EGFR, epidermal growth factor receptor; LN, lymph node; NR, not recorded; NSCLC, non-small cell lung cancer; OPD, oligoprogressive disease; PD, progressive disease;
PFS, progression-free survival; RCC, renal cell carcinoma; RFA, radiofrequency ablation; SACT, systemic anti-cancer therapy; SBRT, stereotactic body radiotherapy; SRS, stereotactic
radiosurgery; TKI, tyrosine kinase inhibitor; XRT, external beam radiotherapy.
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emission tomography/computed tomography (PET/CT) or
diffusion-weighted magnetic resonance imaging (MRI) are
not currently widely used in the metastatic setting.
Although they may help to distinguish patients who are
truly oligoprogressive from those who are likely to display
widespread progression relatively soon after local ablative
therapy, these imaging modalities are costly and unproven
in this setting. The use of functional imaging modalities to
assist with assessing bone disease progression is expanding,
including exploring combined PET/MRI scans [50]. There is
also the need for more cost-effective methods of assessing
patients who may beneﬁt from local therapy. Tumour DNA
from re-biopsy or circulating tumour DNA are potential
predictive markers that require further study.Clinical Experience of Local Ablative
Therapy for Oligoprogressive Disease
Our limited understanding of outcomes after local
ablative treatment for OPD comes mainly from small
retrospective studies in the NSCLC population, with more
limited data in prostate and renal cell cancers [20,51e56].
These studies are summarised in Table 1. The studies all
include patients with OPD treated with local ablative
treatment or palliative radiotherapy for local control. The
studies found a median PFS of 3.3e14 months from the
time of local treatment for OPD to further progression,
with prostate and renal cell cancer patients having the
longest PFS after local ablative treatments. Lung and bone
metastases were the most common EC-OPD sites found
across all patients in most of the studies, with no clear
indication of any particular sites of disease providing a
better prognosis. Univariate and multivariate analyses in
some of the studies show trends suggesting that a shorter
PFS from starting systemic treatment to ﬁrst progression/
local ablative treatment is an important poor prognostic
indicator [20,51,52]. Overall, ablative treatments for OPD
seem to be relatively safe. Six of the seven studies reported
on toxicity and noted minimal toxicities, mostly reportedFig 2. Axial image of a stereotactic body radiotherapy plan for a patient wi
planning target volume. The dose wash key is on the left.
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ported in ﬁve studies, ranging from 4 to 27%
[20,51,52,54,56], and only one grade 4 toxicity due to
postoperative complications was reported [56].
The deﬁnition of OPD varies among studies, with three or
fewer sites of disease being the most common deﬁnition for
OPD, but with some studies including up to ﬁve lesions.
Patients with both intra-cranial OPD and EC-OPD were
included in some series and patients were treated with
varying local ablative or palliative radiotherapy for OPD
with or without continuation of systemic treatments.
The one prospective trial published by Iyenger et al. [57]
in 2014 included 24 NSCLC patients with six or fewer sites of
EC disease progressing after chemotherapy on PET/CT scan.
Patients received SBRT to all active sites and started erloti-
nib until further disease progression. This study found a
median further PFS of 14.7 months and a median overall
survival of 20.4 months. This study highlights a potential
beneﬁt for local ablative therapy in the metastatic setting, a
new approach to treating these patients in combination
with targeted treatments [57].Stereotactic Body Radiotherapy for
Oligoprogressive Disease and Current
Studies
The SBRT technique allows non-invasive ablative doses
to achieve high rates of local lesion control (70e90%) with a
well-tolerated toxicity proﬁle [17]. An example of the high
conformity achieved with a SBRT plan, for a patient with
metastatic prostate cancer with OPD in a solitary sternal
metastasis on abiraterone, is shown in Figure 2. Currently,
the main indication for radiotherapy in metastatic cancers
is to palliate local symptoms. There are few prospective
trials assessing the toxicity and tolerance of SBRT in com-
bination with systemic therapies in patients with wide-
spread disease. Although the prospective studies in OMD
have tended to use SBRT doses with biological equivalent
doses of over 100 Gy, lower doses may be appropriate in
OPD, optimising the balance between achieving local lesionth oligoprogressive disease in the sternum. The pink line indicates the
ed for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Table 2
Current studies open in stereotactic body radiotherapy for oligoprogressive disease (OPD)
Study Estimated
recruitment
Tumour type No. OPD sites Systemic
treatment
Oligoprogression eligibility
criteria
End points
Stereotactic radiotherapy
for metastatic kidney
cancer being treated
with sunitinib
Phase II multicentre
single-arm trial
n ¼ 68 RCC 5 OPD
metastases
Maximum 3
lesions in soft
tissue (EC or CNS
metastases)
First-line sunitinib PD of individual lesion by
RECIST v1.1, 5 mm
increase in size
New metastatic lesion
Progressive enlargement of
a known metastasis on 2
consecutive imaging studies
2e3 months apart, with 5
mm increase
Primary end point: LC rate at 1 year
Secondary end points: PFS, late and
acute toxicity
STOP-NSCLC
(Stereotactic radiotherapy
for oligoprogressive
NSCLC)
Phase II randomised trial
n ¼ 54 NSCLC 5 OPD
metastases,
maximum 3 in any
single organ
(EC or CNS
metastases)
Any cytotoxic or
targeted treatment
for NSCLC
PD of individual lesion by
RECIST v1.1
New metastatic lesion 5
mm
Progressive enlargement of
a known metastasis on 2
consecutive imaging studies
2e3 months apart, with 5
mm increase
Primary end point: PFS
Secondary end points: OS, QoL,
toxicity, LC rate, total time on
chemotherapy, duration of
systemic treatment after SBRT,
location of sites of further
progression
HALT
(Stereotactic body
radiotherapy for the
treatment of OPD)
Multicentre, phase II/III
randomised trial
n ¼ 110 NSCLC with an
actionable
mutation
receiving TKI
treatment
3 EC-OPD TKI Visible OPD on imaging
suitable for SBRT as
determined by HALT virtual
MDT
Primary end point: PFS
Key secondary and exploratory
end points: OS, time to change in
systemic treatment,
patterns of progression, acute and
late toxicity, QoL, ctDNA deep
sequence analysis, PET/CT ﬁndings
in relation to outcome, time to
failure of next treatment
TRAP
(Targeted radiotherapy in
androgen-suppressed
prostate cancer patients)
Multicentre, phase II
single-arm trial
n ¼ 84 CRPC 2 EC-OPD in
lymph nodes,
bone, prostate or
lung only
Abiraterone/
enzalutamide
Visible OPD suitable for SBRT
or clinical progression
Primary end point: PFS
Key secondary and exploratory
end points:
LC, proportion of patients with
detectable ctDNA and ctDNA
response to SBRT, development of
a biomarker panel predicting for
PFS, OS, acute and late toxicity,
QoL, time to delay of next
treatment, subgroup analysis of
PFS of local prostate OPD to
metastatic OPD, ctDNA kinetics to
predict time to progression
CNS, central nervous system; CRPC, castrate-resistant prostate cancer; ctDNA, circulating DNA; EC, extra-cranial; LC, local control; MDT,multidisciplinary team; NSCLC, non-small cell
lung cancer; OS, overall survival; PD, progressive disease; PET/CT, positron emission tomography/computed tomography; PFS, progression-free survival; QoL, quality of life; RCC,
renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumours; SBRT, stereotactic body radiotherapy; TKI, tyrosine kinase inhibitor.
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combined with systemic therapy.
To assess the true clinical beneﬁt for patients of the
addition of SBRT to systemic therapy in OPD, prospective
trials are needed. Current open studies are summarised in
Table 2 and are discussed below.
A phase II, multicentre single-arm study of treatment
with SBRT or stereotactic radiosurgery for oligoprogression
(EC- and intra-cranial OPD) in metastatic renal cell cancer
patients on ﬁrst-line sunitinib is aiming to recruit 68 pa-
tients. The primary end point is local control rate at 1 year,
with secondary end points including PFS, as per RECIST v1.1,
and toxicity. Radiotherapy doses vary from single fraction
treatments to 30 Gy in ﬁve fractions depending on the site
of disease (NCT 02019576).
The STOP-NSCLC trial (NCT 02756793) is a phase II
multicentre randomised trial of SBRT for OPD in patients
with NSCLC on any systemic anti-cancer therapy. The study
aims to recruit 54 patients. Patients are randomised to SBRT
and continuation of systemic therapy versus standard of
care. Standard of care includes continuation of systemic
therapy, observation or switch to the next line of treatment
based on physician preference and patients may also receive
palliative radiotherapy. The primary end point is PFS with
patients allowed to have further SBRT at subsequent
oligoprogression.
The HALT trial (NCT03256981) is a phase IIeIII multi-
centre randomised trial of SBRT for OPD in patients with
advanced NSCLC on a TKI therapy for a targeted mutation
and oligoprogression in three or fewer sites of EC-OPD. The
randomisation is 2:1 for SBRT and continuation of TKI versus
continuation of TKI alone and the trial aims to recruit 110
patients. The primary end point is PFS, deﬁned as lesions
with a 20% increase in size no longer suitable for SBRT or
clinically symptomatic progression or more than three le-
sions with progression. Secondary outcomes include overall
survival, toxicity and quality of life. Radiotherapy doses range
from 30 to 52 Gy in three to eight fractions to OPD lesions; a
lower dose range is used tominimise toxicity in the palliative
setting. Circulating DNA analysis and deep sequencing anal-
ysis of tumour tissue at baseline and at progression, where
available, will also be explored. The trial utilises a virtual
multidisciplinary team (MDT) meeting for the discussion of
all potential trial patients to allow real-time centralised
radiology review byMDTmembers. In the context of no clear
deﬁnition of OPD, the virtual MDT scrutinises entry criteria,
which is informative for recruiting centres.
The TRAP trial (NCT03644303) is a phase II multicentre
single-arm trial aiming to recruit 84 metastatic CRPC pa-
tients with two or fewer sites of OPD in bone, lymph node,
lung or prostate while on abiraterone or enzalutamide.
Patients will receive SBRT at 30 Gy in ﬁve fractions to the
OPD site(s) and continue abiraterone or enzalutamide.
Alternatively, patients with prostate progression may
receive 36 Gy in six fractions. The primary end point is PFS
and secondary end points include local control rates,
prostate-speciﬁc antigen response, overall survival and
toxicity. This study also has an exploratory end point to
identify a biomarker panel predicting for PFS after SBRT,Please cite this article as: Patel PH et al., The Dandelion Dilemma Revisit
Clinical Oncology, https://doi.org/10.1016/j.clon.2019.05.015including diffusion-weighted whole-body MRI scans per-
formed at baseline and circulating tumour DNA.Conclusions
OPD is a recently recognised pattern of disease pro-
gression on systemic anti-cancer therapy. The optimal
approach to the diagnosis and management of this disease
state is not yet established. As observed in prospective
studies of OMD, local ablative therapies, such as SBRT, may
be of clinical beneﬁt. Given the lack of randomised data to
date, local therapy for OPD should ideally be delivered
within a clinical trial in order to gain further insight into the
patient population that may beneﬁt from such an approach.Conﬂict of Interest
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